Currently, despite the well-known molecular heterogeneity of breast cancer and the discovery of significant mutations that distinguish various subtypes, the hormone receptors ER, PR, and HER2 are the only clinically relevant biomarkers and proven therapeutic targets. The gene discussed is NR4A1; the disease is breast carcinoma.